Available Technologies

Back

Paclitaxol Resistant and Dependent Cell Lines

The Technology: Dr. Fernando Cabral at the University of Texas Health Science Center at Houston (UTHSC-H) has developed a series of mutant cell lines with altered sensitivity to antimitotic drugs. Paclitaxel is a drug that binds to polymerized tubulin and inhibits microtubule disassembly. One of the major limitations in using these drugs, however, is the emergence of drug resistant tumor cells. The inventor has found that some tubulin isotypes alter sensitivity to antimitotic drugs by perturbing microtubule assembly, while others have little effect on assembly but increase the binding of specific drugs.

Publications:
• Wang, Y., and Cabral, F (2005). Paclitaxel resistance in cells with reduced β-tubulin. Biochem. Biophys. Acta 1744, 245-255.
• Kamath, K., Wilson. L., Cabral, F., and Jordan, M.A. (2005). βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem. 280, 12902-12907.
• Wang, Y., Win, S., Blade, K., Cooper, G., Menick, D.R., and Cabral, F. (2006). Mutations at Leucine 215 of β-tubulin affect paclitaxel sensitivity by two distinct mechanisms. Biochemistray, 45, 185 - 194

UTHSC-H Ref. No.: 2007-0018-rmd
Inventors: Cabral
Patent Status: N/A
License Available: world-wide; exclusive or non-exclusive

Download Summary (2007-0018)